The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents

Molecular and Cellular Oncology

Volumn 2, Issue 4, 2015, Pages

  Yu, Yan ^a,b   Xie, Yangchun ^a   Cao, Lizhi ^b   Yang, Liangchun ^b   Yang, Minghua ^b   Lotze, Michael T ^a   Zeh, Herbert J ^a   Kang, Rui ^a   Tang, Daolin ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AML; autophagy; erastin; ferroptosis; necroptosis

Indexed keywords

EID: 85024121807     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.1080/23723556.2015.1054549     Document Type: Article

References (32)

1. Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 2014; 29(4):760-769; PMID:25142817
2. Yates JW, Wallace HJ, Jr., Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57:485-8; PMID:4586956
3. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-8; PMID:9321529; http://dx.doi.org/10.1056/NEJM199710093371501
4. Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab 2014; 114(3):397-402; PMID:25533111
5. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, et al. DAMP-mediated autophagy contributes to drug resistance. Autophagy 2011; 7:112-4; PMID:21068541; http://dx.doi.org/10.4161/auto.7.1.14005
6. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58-73; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
7. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516; PMID:17562483; http://dx.doi.org/10.1080/01926230701320337
8. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517:311-20; PMID:25592536; http://dx.doi.org/10.1038/nature14191
9. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370:455-65; PMID:24476434; http://dx.doi.org/10.1056/NEJMra1310050
10. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149:1060-72; PMID:22632970; http://dx.doi.org/10.1016/j.cell.2012.03.042
11. Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia 2015; 29:517-25; PMID:25541151; http://dx.doi.org/10.1038/leu.2014.349
12. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13:828-51; PMID:25323927; http://dx.doi.org/10.1038/nrd4389
13. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3:285-96; PMID:12676586; http://dx.doi.org/10.1016/S1535-6108(03)00050-3
14. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96:1655-69; PMID:10961860
15. Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26:4603-9; PMID:18559876; http://dx.doi.org/10.1200/JCO.2007.14.0418
16. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156:317-31; PMID:24439385; http://dx.doi.org/10.1016/j.cell.2013.12.010
17. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007; 447:864-8; PMID:17568748; http://dx.doi.org/10.1038/nature05859
18. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23:2838-49; PMID:15077147; http://dx.doi.org/10.1038/sj.onc.1207556
19. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13:679-92; PMID:23954936; http://dx.doi.org/10.1038/nri3495
20. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15:234-45; PMID:18355723; http://dx.doi.org/10.1016/j.chembiol.2008.02.010
21. Maldonado EN, Sheldon KL, DeHart DN, Patnaik J, Manevich Y, Townsend DM, Bezrukov SM, Rostovtseva TK, Lemasters JJ. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. J Biol Chem 2013; 288:11920-9; PMID:23471966; http://dx.doi.org/10.1074/jbc.M112.433847
22. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014; 16:1180-91; PMID:25402683; http://dx.doi.org/10.1038/ncb3064
23. Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, Wang H, Cao L, Tang D. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 2015; [Epub ahead of print]; PMID:25728673
24. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 2014; 3:e02523; PMID:24844246; http://dx.doi.org/10.7554/eLife.02523
25. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A 2014; 111:16836-41; PMID:25385600; http://dx.doi.org/10.1073/pnas.1415518111
26. Chung SS. Genetic mutations in acute myeloid leukemia that influence clinical decisions. Curr Opin Hematol 2014; 21:87-94; PMID:24445361; http://dx.doi.org/10.1097/MOH.0000000000000024
27. Khasawneh MK, Abdel-Wahab O. Recent discoveries in molecular characterization of acute myeloid leukemia. Curr Hematol Malig Rep 2014; 9:93-9; PMID:24609756; http://dx.doi.org/10.1007/s11899-014-0200-y
28. Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, Zeh HJ, 3rd, Lotze MT. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011; 13:701-11; PMID:21641551; http://dx.doi.org/10.1016/j.cmet.2011.04.008
29. Yang L, Cao L, Yang M, Tang D, Kang R, Min X, Zhu S, Yu Y. Hsp27: a novel therapeutic target for pediatric M4/M5 acute myeloid leukemia. Oncol Rep 2013; 29:1459-66; PMID:23404246
30. Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med 2015; 212:555-68; PMID:25824823; http://dx.doi.org/10.1084/jem.20140857
31. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014; 14:759-67; PMID:25324125; http://dx.doi.org/10.1038/nri3743
32. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77:1080-6; PMID:1995093